Currently Viewing:
The Academy of Managed Care Pharmacy (AMCP) 2018
Specialty Drug Pipeline Review Focuses on Competition, Cancer Drugs
April 24, 2018
Dr Robert Navarro Discusses Progress in Shift to Value-Based Care
April 24, 2018
Brian Litten Outlines How Medication Therapy Management Can Address Opioid Misuse
April 24, 2018
Who Decides What Value Looks Like in US Healthcare?
April 24, 2018
Dr Brandon Newman Discusses Payer, Academic Medical Center Collaboration
April 25, 2018
Dr Aimee Tharaldson Discusses Key Market Trends in Specialty Pharmacy
April 25, 2018
Migraines in the US Are More Than Just a Pain Problem
April 25, 2018
Market Access Teams Face New Challenges in Pharma
April 25, 2018
Cardiologist Talks About Value of Monoclonal Antibody Evolocumab
April 26, 2018
Dr Somali Burgess on the Role of Patient-Reported Outcomes in Managed Care Pharmacy
April 26, 2018
Dr Tina Joseph Discusses Collaborative Practice Agreements Between Pharmacists, Physicians
April 26, 2018
Navigating the Rocky Waters to Value-Based Healthcare
April 26, 2018
Hemophilia: Treatment Landscape, Costs, and Disease Management
April 26, 2018
Dr Aimee Tharaldson on Recently Approved Specialty Drugs, Upcoming Approvals to Watch
May 05, 2018
Dr Calvin Knowlton Outlines Benefits Seen From Enhanced Medication Therapy Management
May 06, 2018
The Rise of Orphan Drugs for Rare Diseases
May 07, 2018
Dr Robert Navarro Foresees Unintended Consequences From Shift to Value-Based Care
May 12, 2018
Dr Kimberly Lenz: Identifying Patients Most at Risk For Substance Abuse
May 13, 2018
Brian Litten Outlines Challenges With Adopting Medication Therapy Management Services
May 17, 2018
Dr Tina Joseph Outlines Pharmacists' Role in Managing Chronic Diseases, Value-Based Care Models
May 19, 2018
Dr Calvin Knowlton on Innovative Practices in Enhanced Medication Therapy Management
May 20, 2018
Dr Ashley Pappas Discusses Collaboration Between Academic Centers and Payers
May 24, 2018
Dr Robert Navarro on Pharma Implementing Value, Best Practices for Value-Based Contracts
May 25, 2018
Drug Approvals That Dr Aimee Tharaldson Is Keeping an Eye on for 2019
May 27, 2018
Currently Reading
Dr Kimberly Lenz on Implementing, Enforcing Appropriate Opioid Prescribing
June 04, 2018

Dr Kimberly Lenz on Implementing, Enforcing Appropriate Opioid Prescribing

Kimberly Lenz, PharmD, clinical pharmacy manager, MassHealth/Office of Clinical Affairs, University of Massachusetts Medical School discusses initiatives introduced to implement appropriate opioid prescribing, best practices for enforcing appropriate prescribing, and if current opioid restrictions have reduced utilization.


Kimberly Lenz, PharmD, clinical pharmacy manager, MassHealth/Office of Clinical Affairs, University of Massachusetts Medical School discusses initiatives introduced to implement appropriate opioid prescribing, best practices for enforcing appropriate prescribing, and if current opioid restrictions have reduced utilization.

Transcript

What initiatives have been introduced to implement appropriate opioid prescribing?   

When you look across both our plan, as well as other plans across the nation, I think the majority of health plans implement dose limits, quantity limits, duplicate restrictions, and things of that nature, but it really is a wide variety of different plans and initiatives that plans use. Other plans, like ours, use a therapeutic class management program where a multidisciplinary team comes together to reach out to prescribers and discuss treatment plans.

What are best practices to enforce appropriate opioid prescribing?

I think most programs end up using prior authorization because inevitably that’s the tool we have to use, but I think the best approach really is using that in combination with that multidisciplinary team, who’s going to work with the provider hand in glove to kind of decide on safe prescribing, as well as what they think is best for the patient.

Have current opioid restrictions decreased opioid utilization?

It’s a great question, and I’m glad you asked that, because we actually just looked at that in our program. So, I can speak directly to our program, and yes it has worked. So, when we looked over the last 15 years, with our partners at the drug utilization review program at UMass Medical School, we did find a sustained decrease in the average daily dose of our patients who were on high doses of opioids after 3 sequential dose reductions. So right now, we have a high dose limit of 120mg of morphine equivalents, and again, over those 15 years we did see sustained decreases.  

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up